Zogenix Pursues Development of Abuse Deterrent Formulations of Zohydro(TM) ER With Altus Formulation
01. November 2013 16:34 ET
|
Zogenix
SAN DIEGO, Nov. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Receives FDA Approval for Zohydro(TM) ER (hydrocodone bitartrate) Extended-Release Capsules
25. Oktober 2013 17:01 ET
|
Zogenix
SAN DIEGO, Oct. 25, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Provides Update on Zohydro(TM) ER NDA
01. Oktober 2013 18:40 ET
|
Zogenix
SAN DIEGO, Oct. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
Zogenix Reports Second Quarter 2013 Financial Results
08. August 2013 16:01 ET
|
Zogenix
Conference Call and Webcast Today, August 8, at 4:30 p.m. ET
SUMAVEL® DosePro® (sumatriptan injection) Second Quarter 2013 Highlights
Net product revenue of $8.9 million, up 11%...
Zogenix Announces Conference Call and Webcast to Present Second Quarter 2013 Financial Results
05. August 2013 07:30 ET
|
Zogenix
SAN DIEGO, Aug. 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Begins Promotion of Migranal(R) Nasal Spray
01. August 2013 07:30 ET
|
Zogenix
SAN DIEGO, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal(R) Nasal Spray
27. Juni 2013 11:15 ET
|
Zogenix
SAN DIEGO, June 27, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix Launches Improved Migraine Toolbox in Conjunction With National Migraine Awareness Month
25. Juni 2013 07:30 ET
|
Zogenix
SAN DIEGO, June 25, 2013 (GLOBE NEWSWIRE) -- In conjunction with National Migraine Awareness Month and in recognition of the significant unmet needs of migraine sufferers, Zogenix, Inc. (Nasdaq:ZGNX)...
Zogenix Announces Initiatives to Reach Key Business Milestones
05. Juni 2013 08:00 ET
|
Zogenix
SAN DIEGO, June 5, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and...
Zogenix and Battelle to Present Positive, New Data Demonstrating Value of Needle-Free Injection for Biologics
20. Mai 2013 07:30 ET
|
Zogenix
SAN DIEGO and COLUMBUS, Ohio, May 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) and Battelle Memorial Institute today announced new data supporting the value of the DosePro®...